Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConvitVax in Metastatic Breast Cancer
NCT06023277Phase 2Not yet recruiting
- Sponsor
- Jacinto Convit World Organization
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ConvitVax in breast cancer, sponsored by Jacinto Convit World Organization. Primary endpoints: Criteria for disease recurrence at 3 months and Overall safety and tolerability at 1 year. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ConvitVax
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06023277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023277.